Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A, Group A (2007) End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol Off J Am Soc Clin Oncol 25(29):4569–4574. doi:
10.1200/JCO.2006.10.4323
2. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol Off J Am Soc Clin Oncol 23(34):8664–8670. doi:
10.1200/JCO.2005.01.6071
3. German Guideline Program in Oncology (German Cancer Society GCA, AWMF). (2014) Evidenced-based guideline for colorectal cancer, long version 1.0, AWMF registration number: 021-007OL.
http://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/LL_Colorectal_Cancer_1.1_english.pdf
. Accessed 02 January 2017
4. Merkel S, Mansmann U, Hohenberger W, Hermanek P (2011) Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Color Dis : Off J Assoc Coloproctol Great Brit Irel 13(2):123–131. doi:
10.1111/j.1463-1318.2009.02110.x
5. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. doi:
10.1056/NEJMoa040694